SecBot SecBot

ABBV drug pipeline

AbbVie Inc. · 20 rated drugs
$295.03
+0.2% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.7%
1-day, median of 34 events
IV rank
22
IV 25% · HV 22%
Rated drugs
20
1 mixed · 19 neutral
Phase 3 trials
22
3 with results posted

Upcoming catalysts

9 dated
  1. Nov 2026
    Elahere
    Phase 2 primary completion
  2. Dec 2026
    Ranibizumab (LUCENTIS®)
    Phase 3 primary completion
  3. Dec 2026
    Temab-A
    Phase 2 primary completion
  4. Dec 2026
    lutikizumab
    Phase 3 primary completion
  5. Jan 2027
    Upadacitinib
    Phase 3 primary completion
  6. Jan 2027
    Livmoniplimab
    Phase 3 primary completion
  7. Feb 2027
    Decnupaz
    Phase 2 primary completion
  8. Feb 2027
    MEDI0618
    Phase 2 primary completion
  9. Feb 2027
    Elahere
    Phase 2 primary completion

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 3
Time to marketLikely several years away. The Phase 3 trial started recruiting in July 2026 with an estimated 53-month duration, so a potential regulatory filing would be no earlier than 2028-2029 barring accelerated approval based on Phase 2 data.

ABBV-706 Updated Oct 30

What to watch

The next hard catalyst for ABBV-706 is the Phase 3 (NCT07365241) topline readout, but that is likely 2-3 years away given the trial started recruiting in July 2026. Watch for interim analysis announcements and any updates on the Phase 2 SEZanne frontline combination trial. For now, ABBV-706 is a promising but early-stage asset within AbbVie's broad pipeline, not a near-term binary event for the stock.

Bull case
  • Phase 1 data at the recommended Phase 3 dose showed a 56% objective response rate across all R/R SCLC patients and an 82% ORR in second-line patients, with median overall survival of 12.4 months (14.3 months in 2L), which is highly competitive in this difficult-to-treat cancer.
  • ABBV-706 received FDA Orphan Drug Designation for SCLC in October 2024, providing 7-year market exclusivity upon approval and development incentives.
  • The SEZ6 target is distinct from DLL3 (targeted by Amgen's Imdelltra), potentially offering a differentiated mechanism and the possibility of combination or sequential use.
Bear case
  • Competition is intensifying: Amgen's Imdelltra (tarlatamab-dlle) is already FDA-approved for 2L ES-SCLC and recently posted Phase 3 DeLLphi-305 data showing a 58% reduction in death risk when combined with Imfinzi in frontline maintenance, setting a high bar.
  • Phase 1 data showed 93% any-grade treatment-related adverse events and 61% grade 3 or higher TRAEs, indicating meaningful toxicity that could complicate the Phase 3 profile versus standard of care.
  • The Phase 3 trial (NCT07365241) only started recruiting in July 2026 with a 53-month estimated duration, meaning a readout is years away and there is no near-term binary catalyst.
● neutral
Impact
PhasePhase 3 (Filed/PDUFA pending)
Time to marketThe BLA was submitted to the FDA on October 27, 2026. If accepted for filing, a standard review would target a PDUFA decision roughly 10 months from the filing date (approximately August-September 2027). If priority review is granted, the timeline would be approximately 6 months (approximately April-May 2027).

etentamig Updated Oct 30

What to watch

The next catalyst is FDA acceptance of the BLA for filing, expected roughly 60 days from the October 27 submission (late December 2026). If accepted, a PDUFA date will be set: roughly 6 months from filing if priority review is granted, or 10 months for standard review. Watch for whether the FDA grants priority review, which would shorten the timeline and signal regulatory enthusiasm. Also watch for European filing plans and potential partnership/commercialization strategy updates from AbbVie.

Bull case
  • Phase 3 CERVINO trial met both primary endpoints with highly statistically significant results: 74.0% ORR vs 45.7% (p<0.0001) and PFS HR of 0.40 (p<0.0001), a 60% reduction in progression or death risk
  • Differentiated safety profile with monthly IV dosing after a single step-up dose, low CRS rates (28.3%, mostly grade 1, no grade >=3), and lower discontinuation rates (3.6%) than standard therapy (9.6%)
  • Second-generation design with low-affinity CD3 binding domain and silenced Fc tail may enable use in community/outpatient settings beyond specialized centers, expanding addressable patient population
Bear case
  • Crowded BCMA bispecific market with three already-approved competitors: J&J's Tecvayli (teclistamab, approved 2022), Pfizer's Elrexfio (elranatamab, approved 2023), and Regeneron's Linvoseltamab (approved 2025), all targeting the same patient population
  • Etentamig is a small part of AbbVie's $519 billion market cap and diverse portfolio (Skyrizi, Rinvoq, immunology, neuroscience); even a successful launch would have limited impact on the stock
  • Overall survival data were immature at the CERVINO interim analysis; the 12-month OS rate favored etentamig (87.9% vs 72.0%) but did not cross the pre-specified efficacy boundary
● neutral
Impact
PhaseApproved
Time to marketAlready approved and launching in the US as of October 2026.

Juvmo tavapadon Updated Oct 30

What to watch

Juvmo was approved on September 28, 2026, and AbbVie guided to a US launch in October 2026. The next catalysts are Q4 2026 first sales disclosures, Medicare coverage decisions, and real-world adoption data. For a company the size of AbbVie, Juvmo is a pipeline validation story, not a binary event.

Bull case
  • Juvmo is the first and only FDA-approved selective D1/D5 dopamine receptor agonist, a mechanistically novel option in a market where existing agonists target D2/D3 receptors, potentially offering a differentiated safety profile with fewer impulse-control disorders.
  • Phase 3 TEMPO trials showed statistically significant improvements in motor symptoms versus placebo, both as monotherapy in early Parkinson's and as adjunctive therapy with levodopa.
  • AbbVie targets over $5 billion in combined peak sales across its Parkinson's franchise (Juvmo, Vyalev, Duopa), and Citi analysts have called Juvmo a potential billion-dollar drug.
Bear case
  • Juvmo is a small part of AbbVie's massive ~$55B+ revenue base; peak sales estimates of $1-2 billion move the needle less than 2% for the company, limiting stock upside from this drug alone.
  • The drug enters a crowded Parkinson's market with established generic dopamine agonists (pramipexole, ropinirole, rotigotine) that are cheaper and well-known to prescribers.
  • AbbVie did not disclose pricing at approval; Medicare coverage negotiations and ICER scrutiny could pressure reimbursement and slow uptake.
● neutral
Impact
PhasePhase 3
Time to marketLikely several years away; Phase 3 trials are recruiting with primary completion estimated around 2029 for the colorectal cancer trial. Breakthrough Therapy Designation could enable accelerated FDA review if AbbVie files based on interim data, but no filing has been announced.

Temab-A telisotuzumab adizutecan Updated Oct 30

What to watch

The next major catalysts for Temab-A will be interim or final Phase 3 data readouts from the AndroMETa-CRC-560 (NCT07525206) and AndroMETa-Lung-713 (NCT07155187) trials, but these are likely years away (primary completion estimated around 2029 for CRC). Watch for potential accelerated filing based on the Breakthrough Therapy Designations, which could compress the timeline, but no regulatory submission has been announced yet.

Bull case
  • Temab-A received two FDA Breakthrough Therapy Designations in October 2026 for both colorectal cancer and non-small cell lung cancer, a strong regulatory endorsement that can accelerate development and review timelines.
  • Early Phase 1 data (NCT05029882) showed clinically meaningful efficacy in heavily pretreated patients, with the 2.4 mg/kg + bevacizumab dose selected for Phase 3 based on favorable risk-benefit.
  • AbbVie is positioning Temab-A as a 'pipeline-in-a-molecule' across at least seven tumor types, including gastric, esophageal, and head and neck cancers, expanding its addressable market.
Bear case
  • Temab-A is still in Phase 3 trials that are actively recruiting; no pivotal data has been published yet, and the BTDs were based on early-phase data that has not been fully peer-reviewed.
  • The c-Met ADC space is competitive, with other developers pursuing similar targets; Temab-A must differentiate on efficacy and safety to capture market share.
  • For a mega-cap like AbbVie (~$295B market cap, ~$61B revenue), Temab-A is one of many pipeline assets and is unlikely to be a near-term stock-moving catalyst.
● neutral
Impact
PhaseApproved (marketed); supplemental/expansion trials Phase 3
Time to marketAlready on the market — accelerated US approval 2016 (17p-deleted CLL), broader CLL/SLL approval 2019, AML approvals since 2018-2020, and newest first-line CLL combo approval February 2026.

Venclexta venetoclax Updated Aug 3

What to watch

The defining approvals are already in: Venclexta is a marketed CLL/AML franchise with a fresh US label expansion (first-line CLL combo, Feb 2026), so there is no pending PDUFA-style binary to trade, the next meaningful moves will come from quarterly hematology revenue commentary and competitive data from next-generation BCL-2 inhibitors (e.g., BeiGene's sonrotoclax). ABBV's stock is driven far more by its immunology portfolio (Skyrizi/Rinvoq) than by Venclexta, so position sizing should treat this drug as steady cash flow, not a swing factor.

Bull case
  • Approved, established franchise: FDA-approved for CLL/SLL (2019) and AML, supplied by AbbVie (Drugs.com history; FDA pages).
  • Fresh US label expansion: FDA approved the Venclexta + acalabrutinib combination for previously untreated CLL in Feb 2026, first all-oral, fixed-duration regimen in that setting, supported by Phase 3 AMPLIFY (AbbVie/Genentech press releases).
  • Durable efficacy data: final 9-year results from the Phase 3 CLL14 trial presented at EHA 2026 support long-term treatment outcomes in first-line CLL (AbbVie release).
Bear case
  • Expansion setback: Phase 3 VERONA showed venetoclax + azacitidine did NOT improve overall survival in higher-risk MDS vs placebo, no MDS label expansion (Dana-Farber release; CURE Today).
  • Competitive threat: next-generation BCL-2 inhibitors (notably BeiGene's sonrotoclax) are advancing in CLL and could undercut Venclexta's pricing/positioning over time.
  • No pending regulatory binary: the defining approvals have passed, so the stock gets no Venclexta-specific PDUFA/readout catalyst in the next ~12 months; the Phase 3 CANOVA multiple-myeloma program has not produced a filing, and a post-transplant AML Phase 3 was terminated.
● neutral
Impact
PhasePhase 3
Time to marketIf Phase 3 succeeds, potential regulatory filing would be around 2029-2030 based on the estimated December 2029 primary completion date of the pivotal trial.

ABBV-1480 Updated Oct 30

What to watch

The next hard catalyst for ABBV-1480 is the Phase 3 AMUR-Lung-01 (NCT07756645) data readout, but with estimated primary completion in December 2029, no binary event is expected within the next 12 months. Watch for interim analysis announcements, expansion into additional solid tumor indications, and any early efficacy signals from the ongoing Phase 3 enrollment. For a company of AbbVie's size, this is one of many pipeline assets and not a near-term value driver.

Bull case
  • Phase 1b data showed a 90.0% objective response rate in squamous NSCLC and 75.9% in non-squamous NSCLC when combined with platinum-based chemotherapy at the recommended Phase 3 dose (10 mg/kg), a strong early signal.
  • ESMO 2026 data showed ABBV-1480 monotherapy achieved a 61.9% ORR and 15.2-month median PFS in first-line PD-L1-positive NSCLC (n=22), supporting its potential as a monotherapy option.
  • The differentiated tetravalent design uses VEGF-triggered tumor enrichment, which may reduce systemic anti-VEGF toxicity compared to competitors like ivonescimab.
Bear case
  • ABBV-1480 is entering a crowded PD-1/VEGF bispecific field where ivonescimab (Summit/Akeso) and pumitamag are already advanced, and Keytruda (pembrolizumab) is the entrenched standard of care in 1L NSCLC.
  • Phase 1b data (90% ORR in squamous NSCLC) comes from small sample sizes (n=30 squamous, n=29 non-squamous) and may not replicate in the large Phase 3 trial.
  • AbbVie paid $650M upfront plus up to $4.95B in milestones for ex-China rights, a large bet on an asset that was still in Phase 2 in China at deal signing, with no guarantee of regulatory success.
● neutral
Impact
PhasePhase 2
Time to marketAt least 4-6 years. Phase 2 primary completion is estimated March 2028, followed by Phase 3 trials and regulatory filing, putting potential approval in the 2030-2032 timeframe if all goes well.

ABBV-295 Updated Oct 30

What to watch

The next catalyst is the Phase 2 topline readout, estimated around March 2028. For a mega-cap like AbbVie, even a strong Phase 2 result would be a modest share-price driver. Watch for any interim data presentations at medical conferences in 2027 and for Gubra milestone announcements tied to Phase 2 progress.

Bull case
  • Phase 1 data showed 7.8%-9.8% weight loss at 12 weeks on once-weekly dosing, competitive with early-stage GLP-1 data, with a favorable tolerability profile.
  • ABBV-295 targets amylin receptors, a non-incretin mechanism distinct from GLP-1/GIP agonists, potentially enabling combination therapy and differentiation.
  • The 11-12 day half-life supports flexible dosing (weekly, every-other-week, or monthly), a potential convenience advantage.
Bear case
  • ABBV-295 is a Phase 2 asset at a mega-cap pharma (AbbVie ~$295B market cap), so even a successful readout will have a modest impact on the stock.
  • The obesity market is intensely competitive, dominated by Novo Nordisk's Wegovy/Ozempic (GLP-1) and Eli Lilly's Zepbound/Mounjaro (GIP/GLP-1). Amylin analogs are an unproven mechanism at scale.
  • Phase 1 data was mostly in male participants (88.3%), raising questions about generalizability to the broader obesity population.
● neutral
Impact
PhasePhase 2
Time to marketMultiple years away from potential approval. The IBD combination is in Phase 2b with AbbVie evaluating Phase 3 acceleration options, meaning an approved product is likely 5+ years away if development continues successfully. The HIV program faces a more uncertain path given mixed Phase 2 results.

ABBV-382 trosunilimab Updated Oct 30

What to watch

The next catalyst for ABBV-382 is the ongoing Phase 2b platform basket study (M26-266) evaluating Skyrizi + ABBV-382 in Crohn's disease and ulcerative colitis, which began enrollment in July 2026. No specific readout date has been announced. AbbVie has indicated it is evaluating Phase 3 acceleration options for the IBD combination, so a Phase 3 start announcement could be a positive catalyst. The HIV program's mixed Phase 2 results make further development in that indication uncertain.

Bull case
  • The Skyrizi + ABBV-382 combination (ABBV-466) showed compelling Phase 2a data showing 30.2% endoscopic remission at Week 2 (vs 21.3% for Skyrizi alone and 18% for ABBV-382 alone), with rates rising to 40.5% by Week 24, suggesting a clear additive benefit from dual mechanism targeting.
  • AbbVie is accelerating Phase 3 development plans for the IBD combination, indicating internal confidence in the asset's potential to extend Skyrizi's franchise life.
  • The HIV functional cure approach addresses a large unmet need (38 million people living with HIV globally) and the Phase 2 showed delayed viral rebound in about a quarter of patients, providing proof of mechanism.
Bear case
  • ABBV-382 is one of many pipeline programs at a mega-cap pharma company; even successful Phase 3 data would have a modest impact on AbbVie's share price given the company's scale and diversified revenue base.
  • The HIV functional cure data was mixed: the combination delayed but did not prevent viral rebound long-term, and the path to a true functional cure remains uncertain.
  • The IBD space is highly competitive with multiple approved therapies (Skyrizi, Stelara, Entyvio, Rinvoq, Remicade biosimilars) and the combination will need to show clear differentiation to justify premium pricing.
● neutral
Impact
PhasePhase 2
Time to marketAt least 4-6 years away. The drug is in Phase 2; a large Phase 2b study began in July 2026 with an estimated completion date of October 2031. Phase 3 trials and regulatory review would follow.

ABBV-466 risankizumab + trosunilimab Updated Oct 30

What to watch

The next catalyst for ABBV-466 is further data readouts from the ongoing Phase 2b platform study (M26-266 / NCT07697456), which began enrolling ~2,000 patients in July 2026 across Crohn's disease and ulcerative colitis. No specific topline readout date has been announced. Given AbbVie's diversified pipeline and market cap, ABBV-466 data alone is unlikely to drive a major share-price move in either direction in the near term.

Bull case
  • ABBV-466 met its primary endpoint in Phase 2a, achieving 30.2% endoscopic remission at Week 12 vs 21.3% for Skyrizi alone and 18.0% for trosunilimab alone, a clinically meaningful additive benefit.
  • The efficacy gap widened at Week 24 (40.5% vs 22.4% and 20.0%), suggesting the dual mechanism may produce durable responses.
  • Safety was comparable across arms (SAEs 10.4% vs 9.6% and 9.0%), with no unexpected safety signals from combining the two biologics.
Bear case
  • The Phase 2a TARGET-CD study was open-label (no placebo control), which limits the reliability of the efficacy signal and leaves room for confounding.
  • SAE rates were slightly higher for ABBV-466 (10.4%) vs risankizumab (9.6%) and trosunilimab (9.0%) monotherapy, and combining two biologics could raise long-term safety questions.
  • ABBV-466 is essentially designed to cannibalize AbbVie's own blockbuster Skyrizi ($10B+ H1 2026 revenue), creating an internal revenue transition risk.
● neutral
Impact
PhaseApproved (FDA approval 2021-09-28 per SecBot catalyst record); post-approval Phase 3 programs completed
Time to marketAlready on the US market since September 2021 as Qulipta (atogepant); "Aquipta" is the same molecule's international/EU brand name.

Aquipta atogepant Updated Aug 3

What to watch

ABBV's analyst tape is bullish (mean target ~$270 vs ~$251 price), but that thesis rests on the whole portfolio, not this drug.

Bull case
  • Already approved: SecBot's FDA-catalyst record shows QULIPTA FDA approval on 2021-09-28 for ABBV, the biggest regulatory binary has passed and the drug is on the market.
  • Three AbbVie Phase 3 trials (vs topiramate, n=545; +Botox in chronic migraine; Japanese episodic migraine, n=524) are COMPLETED with results posted, data that can support label expansions and international launches.
  • Parent-company tape is bullish: ABBV analyst consensus shows 31 Buy/Strong-Buy vs 8 Hold/0 Sell, with a mean price target of $270.39 vs a ~$250.94 quote, and July 2026 actions included target raises to $300 (Barclays), $300 (BMO Capital), $295 (Wells Fargo).
Bear case
  • No pending regulatory decision or dated readout for atogepant in the next ~12 months per SecBot's FDA-catalyst data, an approved drug with no binary catalyst, and at a mega-cap like ABBV this one product is a modest slice of company value (recent ABBV FDA news concerns other drugs: Venclexta sNDA approval 2026-04-29, Epkinly sBLA approval 2026-02-04, trenibotulinumtoxinE CRL 2026-04-29).
  • Crowded CGRP/migraine-prevention market with branded rivals (notably Pfizer's rimegepant/Nurtec ODT and multiple injected antibodies) plus eventual oral-gepant competition and payer pressure, pricing/commercial share is the ongoing fight.
  • ABBV's quant snapshot is only mildly constructive (compositeScore 20, RSI-14 51.8, forward P/E 17.77) and recent insider filings are routine director RSU/SEU grants, not open-market buying signals.
● neutral
Impact
PhaseApproved (FDA approved April 2009; marketed)
Time to marketAlready approved and on the U.S. market (since April 2009)

Creon pancrelipase Updated Aug 3

What to watch

Watch AbbVie's quarterly segment disclosures and the PERT competitive landscape (generic entry, pricing) for erosion signals, since those are the only ways this drug shows up in the stock's fundamentals.

Bull case
  • Category leader in a sticky, lifelong-dosing market: EPI patients (cystic fibrosis, chronic pancreatitis, pancreatectomy) typically stay on PERT for years, favoring brand loyalty and switch inertia.
  • One market-research source estimates CREON at roughly $1.2–1.6 billion in 2024 U.S. revenues and calls it the dominant domestic PERT brand (third-party estimate, not AbbVie-disclosed).
  • Market backdrop is still growing: the pancreatic enzyme replacement market is estimated at ~$1.85B in 2025, projected to ~$2.8B by 2032 (~6.1% CAGR), per a separate market report.
Bear case
  • No near-term binary: CREON has no pending PDUFA, pivotal readout, or label-expansion decision in the next ~12 months, so it cannot drive a dated share-price catalyst for ABBV.
  • Generic/competitor erosion: a market-research snippet claims a Viatris 'generic Creon' posted roughly $0.3–0.4B in 2024 and is eroding the originator via AB-equivalence (third-party claim, unverified).
  • Concentration risk in reverse: CREON is a small fraction of AbbVie's overall revenue, so even a significant CREON-specific event would move ABBV only marginally, not a re-rating driver.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and on the market — FDA original approval granted 2026-05-27 (BLA 761460).

Decnupaz pivekimab sunirine Updated Aug 3

What to watch

Watch AbbVie earnings calls for first commercial-update commentary on Decnupaz (launch ramp, pricing, and any label-expansion trial starts), but treat this as a rounding-error program for a ~$250B company rather than a stock-driving catalyst.

Bull case
  • FDA approved Decnupaz (pivekimab sunirine-pvzy) on 2026-05-27 as a Type 1 New Molecular Entity under priority review with orphan-drug designation (BLA 761460), an unambiguous regulatory success for AbbVie.
  • Orphan designation gives Decnupaz a rare-disease niche with potential orphan exclusivity and premium pricing dynamics typical of such drugs, inside a company with deep commercial infrastructure.
  • ABBV carries no Decnupaz-specific overhang: analyst consensus is 'buy' (22 buy + 9 strong buy, 0 sell; mean price target $270.39, ~11.6% implied upside vs. the $250.94 quote), and the stock trades near its 52-week high of $267.47.
Bear case
  • No upcoming hard catalyst: the approval binary already passed, and no PDUFA, pivotal readout, or advisory-committee date for Decnupaz appears in local FDA/catalyst data, nothing scheduled to move the stock on this name within ~12 months.
  • Concentration is extreme in the wrong direction for this drug: at ~$250B market cap, one niche orphan oncology launch is a rounding error; even a strong launch is unlikely to move ABBV.
  • Company-level regulatory risk exists regardless: FDA issued a Complete Response Letter to AbbVie for trenibotulinumtoxinE on 2026-04-29 (SEC-extracted catalyst record), a reminder that AbbVie's regulatory calendar is not risk-free.
● neutral
Impact
PhaseUnverified this session — external web search unavailable (zero results on all queries) and local FDA/trial databases co
Time to marketCould not be verified this session — external web research returned no results and local FDA/trial data has no Elahere records.

Elahere mirvetuximab soravtansine Updated Aug 3

What to watch

Re-run research once web connectivity returns; meanwhile, watch AbbVie quarterly earnings commentary (latest earnings 8-K filed 2026-07-31) for Elahere sales and any regulatory updates, and note the company also absorbed an FDA Complete Response Letter on another asset (trenibotulinumtoxinE, 2026-04-29), portfolio-level regulatory risk exists.

Bull case
  • Ticker verified: AbbVie Inc. (ABBV, NYSE, Pharmaceutical Preparations) is a live issuer, consistent with the filing hint's developer identification.
  • The parent's oncology portfolio shows recent regulatory wins, local FDA catalyst data records a Venclexta sNDA approval (2026-04-29) and an Epkinly sBLA approval (2026-02-04), evidence the franchise Elahere sits in is being actively advanced.
  • Street support for AbbVie is solid: consensus shows 22 Buy + 9 Strong Buy vs 8 Hold and 0 Sell, with a mean price target of $270.39 (median $280) versus the $250.94 price, roughly 11.6% implied upside.
Bear case
  • Concentration risk in reverse: Elahere is one product inside a mega-cap diversified pharma, so even major Elahere news has limited ability to move ABBV, there is no single-asset binary setup here.
  • Company-level regulatory risk exists: FDA issued a Complete Response Letter to AbbVie for trenibotulinumtoxinE on 2026-04-29, a reminder that portfolio assets can face setbacks independent of Elahere.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since December 2002 in the US (FDA approval catalyst recorded for 2002-12-31); the originator franchise is in its late-life, biosimilar-eroded phase.

Humira adalimumab Updated Aug 2

What to watch

Treat Humira purely as an erosion/run-rate metric inside AbbVie's quarterly reports, expect continued -30%+ YoY declines and do not trade ABBV on Humira headlines, since the stock's thesis is driven by Skyrizi/Rinvoq growth, the Apogee close, and the broader pipeline. If you want Humira-specific exposure, the action is in the biosimilar makers, not the originator.

Bull case
  • Still generates real cash: Humira contributed $756M of revenue in Q2 2026 even while eroding -35.9% YoY (AbbVie Q2 2026 8-K), so the franchise is a cash cow in managed decline rather than a dead asset.
  • Erosion is fully offset by successors: same-quarter Skyrizi revenue $5.505B (+24.4%) and Rinvoq $2.525B (+24.5%) powered total revenue up 10.2% YoY (Q2 2026 8-K), so Humira's decline no longer threatens the company's growth story.
  • Street is broadly constructive on ABBV overall: consensus shows 22 buy + 9 strong buy vs 0 sell, mean price target $270.39 (≈11.6% above last close $250.94), with July 2026 target raises from Barclays ($300), BMO Capital ($300), Wells Fargo ($295), RBC and JPMorgan ($280).
Bear case
  • Deep, durable biosimilar competition: multiple adalimumab biosimilars are actively marketed and labeled, Celltrion's adalimumab-aaty (FDA safety labeling Jul 2026), Pfizer's Abrilada (May 2026), Samsung Bioepis' Hadlima (supplemental approvals May 2025), keeping -30%+ annual erosion on the originator.
  • Humira is now a small, shrinking slice of AbbVie: ~4.4% of Q2 2026 revenue ($756M of $16.99B), so its decline is a headwind that dilutes growth but that investors already fully discount, no upside left and continued downside to its run rate.
  • Patent-expired franchise with no regulatory upside: the originator has no pending label expansion or approval decision, so the only future Humira headlines are more erosion, more payer/rebate pressure, and possible further price concessions.
● neutral
Impact
PhaseApproved / marketed (Phase 3 completed for the pediatric ages 2–5 sNDA)
Time to marketAlready marketed in the U.S. since FDA approval in 2012; the only pending item was the pediatric (ages 2–5) label-expansion sNDA decided around its May 24, 2026 PDUFA date.

Linzess linaclotide Updated Aug 3

What to watch

For ABBV holders, Linzess is immaterial to the thesis, treat it as steady, profitable co-marketed revenue, not a catalyst. Watch the 2026-08-06 IRWD Q2 earnings print (the co-commercialization partner) for Linzess U.S. net-sales momentum and any update on the ages 2–5 pediatric label decision from the May 2026 PDUFA, which the local data does not yet record as approved or rejected.

Bull case
  • Steady, profitable commercial asset: Q1 2026 LINZESS U.S. net sales hit $272.5M, up ~97% y/y on improved net pricing (IRWD 8-K/10-Q period report, local earnings analysis 2026-05-07).
  • AbbVie management (via IRWD) guided full-year 2026 LINZESS U.S. net sales of $1.125–1.175B with adj. EBITDA >$300M for Ironwood, a clear revenue floor for the brand.
  • Label-expansion optionality: FDA granted PRIORITY review to the pediatric ages 2–5 sNDA (PDUFA May 24, 2026) after a completed 123-patient AbbVie Phase 3 (NCT05652205); if approved, it extends the product's reach into a new patient population.
Bear case
  • No forward catalyst: the only scheduled regulatory binary (May 24, 2026 pediatric PDUFA) has passed and its outcome is unrecorded; for ABBV specifically, Linzess is a rounding error inside a mega-cap portfolio (~$250B market cap, $250.94/share at last quote).
  • For the co-partner IRWD, economics are pressured: total revenue fell from $351.4M (2024) to $296M (2025), a decline that the Q1 2026 net-pricing surge only partially offsets.
  • Mature GI market with multiple branded competitors and looming generic/biosimilar-style erosion typical of a drug first approved in 2012, patent life is finite and the model depends on continued net-pricing improvement.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and on the market — US FDA approval recorded 2017-08-03, with a further FDA approval/label expansion recorded 2021-06-10

Maviret glecaprevir and pibrentasvir Updated Aug 3

What to watch

Maviret/Mavyret is a mature, already-approved hepatitis C franchise inside a $253/share mega-cap; there is no near-term drug-specific binary to trade, so it should not be treated as a catalyst stock. Watch ABBV quarterly earnings (Q2 2026 reported 2026-07-31) for the direction of the shrinking HCV line, and the company's larger pipeline readouts (e.g., ABBV-951 Parkinson's, Bimatoprost SR) if you want an ABBV catalyst.

Bull case
  • Proven, pan-genotypic, all-oral hepatitis C cure that has been on the market since the FDA approval recorded 2017-08-03, with a further FDA approval event on 2021-06-10 showing the label was expanded after launch.
  • ABBVIE the stock is broadly supported: analyst consensus is 22 Buy / 9 Strong Buy / 8 Hold / 0 Sell (period 2026-07-01) with a mean price target of $270.39 and median of $280 vs. a live price of $253.30 (implied upside ~10.5%), and 62 tracked 13F managers held ABBV at 2026-Q2.
  • The hepatitis C therapy class cured its patient population, a lasting legacy product that no longer needs clinical risk-taking; 31 analyst actions in the past 180 days were almost all maintains with raised price targets.
Bear case
  • No hard, dated catalyst: the drug is already approved with no pending PDUFA/pivotal readout, and its own approval catalysts moved ABBV only +0.4% (2017) and +1.25% (2021) over one day, it is not a meaningful share-price driver.
  • As one product inside a mega-cap (~$253/share, market-wide diversified portfolio), even franchise-level news is immaterial to ABBV's valuation; the stock's real near-term drivers are elsewhere (Q2 2026 earnings reported 2026-07-31; pending ABBV-951 and Bimatoprost SR readouts).
● neutral
Impact
PhaseApproved (marketed)
Time to marketAlready on the market — FDA-approved since September 2015 (per local catalyst record). No unapproved Vraylar submission or PDUFA date is verifiable this session.

Vraylar cariprazine Updated Aug 2

What to watch

Vraylar is an established, marketed revenue contributor inside AbbVie, not a standalone binary catalyst, don't buy the stock expecting a Vraylar-specific event.

Bull case
  • Established franchise: SecBot's catalyst record confirms Vraylar FDA approval on 2015-09-17 under ABBV, roughly a decade of marketed commercial history in schizophrenia/bipolar space.
  • Parent-stock backdrop is supportive: analyst consensus on ABBV is 22 buy / 9 strong buy / 8 hold / 0 sell (period 2026-07-01), with mean price target $270.39, median $280, and ~11.6% implied upside vs. the $250.94 last price.
  • ABBV 13F data shows broad tracked-manager accumulation (adds/doubles in 2025-Q4 through 2026-Q2, e.g., Bridgewater +113.7%, Millennium +3297% shares-change on a small base, Fisher +1347%), a favorable institutional tape around the company, though not Vraylar-specific.
Bear case
  • No near-term binary: no Vraylar PDUFA, pivotal readout, or label decision appears in SecBot's FDA/pipeline data for the past year, approved products don't generate the step-change events traders can date.
  • Mega-cap dilution: SecBot's local catalyst-outcome data shows ABBV stock averages just -0.47% (1-day) across 5 recorded FDA-approval events; the 2015 Vraylar approval itself predates the local 730-day window, so any Vraylar news would move this ~$440B company modestly at most.
  • Unverifiable risk overhang: patent-expiry/generic competition and the long-acting injectable (LAI) timeline could not be checked because the external web layer was down all session, treat competitive erosion as an open, unquantified risk.
● neutral
Impact
PhasePhase 1
Time to marketLikely several years away. The drug is still in Phase 1 dose expansion with no registrational trial initiated. If Phase 1 data support advancement, Phase 2/3 trials would need to be completed before any regulatory filing, likely 2028-2030 at the earliest.

ABBV-2001 isb 2001 Updated Oct 30

What to watch

Watch for Phase 1 dose-expansion data from the TRIgnite-1 study (NCT05862012), which could come at a medical meeting in 2027. Positive data would support advancement to Phase 2/3, but ABBV-2001 is a small pipeline component for AbbVie, so even strong readouts are unlikely to move the stock materially. The more relevant near-term catalyst for AbbVie's multiple myeloma franchise is the etentamig (ABBV-383) BLA, submitted to the FDA on October 27, 2026.

Bull case
  • ABBV-2001 is a first-in-class trispecific T-cell engager targeting both BCMA and CD38 simultaneously, which could overcome resistance mechanisms that limit existing bispecific antibodies. Phase 1 data showed a 79% ORR and 30% CR/sCR rate in heavily pretreated patients, including 73% ORR in patients who had already failed prior BCMA-targeted therapies.
  • The drug has shown a favorable safety profile with no dose-limiting toxicities and mostly mild CRS, which could support outpatient administration and a broad label if later trials succeed.
  • AbbVie has deep expertise in multiple myeloma (etentamig BLA just filed) and strong commercial infrastructure, giving ABBV-2001 a clear development and launch pathway if Phase 2/3 data are positive.
Bear case
  • ABBV-2001 is still in Phase 1 dose expansion with no pivotal trial started, meaning regulatory approval is likely years away (if it ever comes).
  • The multiple myeloma treatment landscape is crowded with approved bispecific antibodies from J&J (Tecvayli), Pfizer (Elrexfio), and Regeneron (Lynozyfic), plus AbbVie's own etentamig (ABBV-383) BLA was just submitted. ABBV-2001 will need to differentiate on efficacy, safety, or convenience to carve out a role.
  • AbbVie paid $700M upfront and up to $1.925B total in milestones for this asset, a significant outlay for a Phase 1 drug that has not yet demonstrated a registrational path.
● neutral
Impact
PhasePhase 1/2
Time to marketSurzetoclax is in Phase 1/2 trials with no regulatory submissions filed. Assuming successful development, potential approval is likely several years away (5+ years), though this is highly uncertain at this early stage.

surzetoclax Updated Oct 30

What to watch

Surzetoclax has no scheduled PDUFA date, pivotal readout, or regulatory decision within the next 12 months. The next meaningful event would be early efficacy/safety data from the ongoing Phase 1/2 platform study (NCT06953960) or the Phase 1 CLL/SLL study (NCT06291220), but no readout dates have been announced. For ABBV investors, surzetoclax is a pipeline filler, not a stock-moving catalyst.

Bull case
  • Next-generation BCL-2 inhibitor designed with macrocyclic elements for improved molecular properties and sub-nM affinity for BCL2 (source: ashpublications.org Blood article)
  • High selectivity over BCL-XL and MCL-1, which could reduce dose-limiting toxicities like tumor lysis syndrome compared to venetoclax (source: newdrugapprovals.org)
  • Potentially best-in-class BCL-2 inhibitor for t(11;14) multiple myeloma, with preclinical data showing superior tumor growth inhibition vs venetoclax, sonrotoclax and lisaftoclax (source: LARVOL/IMS 2026 abstract)
Bear case
  • Very early-stage (Phase 1/2) with no efficacy data from controlled trials yet published; most early-stage oncology drugs fail to reach approval
  • Competes in a crowded BCL-2 inhibitor space including AbbVie's own marketed venetoclax (Venclexta), plus sonrotoclax, lisaftoclax, and others
  • For AbbVie, surzetoclax is a tiny pipeline asset; even if successful, it would likely cannibalize venetoclax sales and is not a meaningful revenue driver for the company

Other drugs in filings and trials

no drug report yet
  • trenibotulinumtoxinE Last: Complete response letter · Apr 29, 2026
  • Epkinly Last: Approval · Feb 4, 2026
  • EMRELIS Last: Approval · May 14, 2025
  • EMBLAVEO Last: Approval · Feb 7, 2025
  • VYALEV Last: Approval · Oct 16, 2024
  • RINVOQ LQ Last: Approval · Apr 26, 2024
  • SKYRIZI Last: Approval · Jun 16, 2022
  • VUITY Last: Approval · Oct 28, 2021
  • ORIAHNN (COPACKAGED) Last: Approval · May 29, 2020
  • DURYSTA Last: Approval · Mar 4, 2020
  • UBRELVY Last: Approval · Dec 23, 2019
  • RINVOQ Last: Approval · Aug 16, 2019
  • ORILISSA Last: Approval · Jul 23, 2018
  • NORVIR Last: Approval · Jun 7, 2017
  • VIEKIRA XR Last: Approval · Jul 22, 2016
  • BYVALSON Last: Approval · Jun 3, 2016
  • TECHNIVIE Last: Approval · Jul 24, 2015
  • VIBERZI Last: Approval · May 27, 2015
  • KYBELLA Last: Approval · Apr 29, 2015
  • AVYCAZ Last: Approval · Feb 25, 2015
  • DUOPA Last: Approval · Jan 9, 2015
  • NAMZARIC Last: Approval · Dec 23, 2014
  • VIEKIRA PAK (COPACKAGED) Last: Approval · Dec 19, 2014
  • DALVANCE Last: Approval · May 23, 2014
  • FETZIMA Last: Approval · Jul 25, 2013
  • DELZICOL Last: Approval · Feb 1, 2013
  • OXYTROL FOR WOMEN Last: Approval · Jan 25, 2013
  • ABBV-932 1 trial
  • ABBV-951 2 trials
  • Bimatoprost (SR) 1 trial
  • Bimatoprost SR 1 trial
  • BOTOX 2 trials
  • Elezanumab 1 trial
  • Eluxadoline 1 trial
  • GM-2505 1 trial
  • MEDI0618 1 trial
  • Memantine 1 trial
  • OnabotulinumtoxinA 1 trial
  • Ranibizumab (LUCENTIS®) 1 trial
  • Telisotuzumab vedotin 1 trial
  • Upadacitinib 1 trial

Past FDA events & how the stock moved

34 events
DateDrugEvent1 day5 days
Apr 29, 2026trenibotulinumtoxinEComplete response letter+6.9%+3.7%
Apr 29, 2026VenclextaApproval+6.9%+3.7%
Feb 4, 2026EpkinlyApproval−2.9%−2.1%
May 14, 2025EMRELISApproval−3.4%−3.3%
Feb 7, 2025EMBLAVEOApproval−1.4%−0.1%
Oct 16, 2024VYALEVApproval−1.7%−2.1%
Apr 26, 2024RINVOQ LQApproval−3.5%−2.1%
Jun 16, 2022SKYRIZIApproval+0.1%+10.3%
Oct 28, 2021VUITYApproval+5.8%+8.0%
Sep 28, 2021AquiptaApproval+1.0%+1.7%
Jun 10, 2021MaviretApproval+1.3%+0.8%
May 29, 2020ORIAHNN (COPACKAGED)Approval+0.7%+4.2%
Mar 4, 2020DURYSTAApproval+3.5%−3.1%
Dec 23, 2019UBRELVYApproval+0.6%−0.8%
Aug 16, 2019RINVOQApproval+5.7%+4.8%
Apr 23, 2019SKYRIZIApproval+0.7%+1.6%
Jul 23, 2018ORILISSAApproval+3.0%+2.9%
Aug 3, 2017MaviretApproval+0.4%−0.4%
Jun 7, 2017NORVIRApproval+1.3%+3.9%
Jul 22, 2016VIEKIRA XRApproval+0.7%+3.7%
Jun 3, 2016BYVALSONApproval−3.5%−6.3%
Apr 11, 2016VenclextaApproval+2.4%+3.4%
Sep 17, 2015VraylarApproval+2.9%−4.9%
Jul 24, 2015TECHNIVIEApproval−1.7%−0.7%
May 27, 2015VIBERZIApproval+2.1%+1.4%
Apr 29, 2015KYBELLAApproval−2.8%−3.8%
Feb 25, 2015AVYCAZApproval−0.6%−1.0%
Jan 9, 2015DUOPAApproval−2.8%−3.9%
Dec 23, 2014NAMZARICApproval−1.1%−2.3%
Dec 19, 2014VIEKIRA PAK (COPACKAGED)Approval−1.4%−1.1%
May 23, 2014DALVANCEApproval+0.7%+1.0%
Jul 25, 2013FETZIMAApproval+2.6%+3.7%
Feb 1, 2013DELZICOLApproval+1.6%−1.2%
Jan 25, 2013OXYTROL FOR WOMENApproval−1.5%−0.8%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
DecnupazIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaPhase 2Active not recruiting218Feb 2027
MEDI0618A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic MigrainePhase 2Active not recruiting309Feb 2027
ElahereA Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionPhase 2Active not recruiting108Feb 2027
UpadacitinibSafety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic DermatitisPhase 3Active not recruiting99Jan 2027
LivmoniplimabA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Phase 3Active not recruiting89Jan 2027
Ranibizumab (LUCENTIS®)Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDPhase 3Active not recruiting671Dec 2026
Temab-AStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and BevacizumabPhase 2Active not recruiting280Dec 2026
lutikizumabA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaPhase 3Active not recruiting1,400Dec 2026
ElahereMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerPhase 2Active not recruiting125Nov 2026
—A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult ParticipantsPhase 3Completed252Sep 3, 2026
ABBV-444A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye DiseasePhase 3Completed261Aug 21, 2026
EluxadolineStudy to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in ChildrenPhase 2Completed272Aug 17, 2026
VenclextaA Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Phase 3Active not recruiting265Aug 2026
RanibizumabRGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)Phase 2Active not recruiting146Aug 2026
GM-2505A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDDPhase 2Completed126Jul 27, 2026
HumiraStudy to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisPhase 3Completed487Jul 15, 2026
—ELAPR002f Injectable Gel in the Treatment of Atrophic Acne ScarsPhase 3Completed157Jul 14, 2026
Telisotuzumab vedotinStudy of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerPhase 2Active not recruiting270Jul 2026
Bimatoprost SRLong-term Safety and Efficacy Extension Trial of Bimatoprost SRPhase 3Completed455Jun 19, 2026
Topical SteroidRGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)Phase 2Completed139Jun 18, 2026
VenclextaVenetoclax After TKI to Target Persisting Stem Cells in CMLPhase 2Completed10May 31, 2026
ABBV-951Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's DiseasePhase 3Completed118Apr 27, 2026
ABBV-951Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's DiseasePhase 3Completed130Apr 17, 2026
OnabotulinumtoxinAA Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult ParticipantsPhase 3Completed150Apr 3, 2026
MemantineMemantine for the Treatment of Cognitive Impairment in Systemic Lupus ErythematosusPhase 2Completed111Feb 28, 2026
—A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin QualityPhase 3Completed135Feb 5, 2026
—Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle GlaucomaPhase 3Completed74Feb 4, 2026
VenclextaVenetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic SyndromePhase 2Terminated51Feb 3, 2026
ElezanumabSafety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)Phase 2Completed60Jan 26, 2026
—A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult ParticipantsPhase 3Completed61Dec 5, 2025
JuvmoOpen-label Trial in Parkinson's Disease (PD)Phase 3Completed992Dec 1, 2025
BOTOXA Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle ProminencePhase 3Completed202Nov 25, 2025
—Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC PatientsPhase 2Completed · results194Nov 17, 2025
ABBV-932Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II DisorderPhase 2Completed161Nov 12, 2025
BOTOXA Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult ParticipantsPhase 3Completed207Nov 10, 2025
VenclextaStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Phase 2Completed · results20Oct 9, 2025
VenclextaA Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)Phase 3Terminated · results465Sep 23, 2025
ABBV-382A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382Phase 2Terminated · results163Sep 22, 2025
LinzessA Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional ConstipationPhase 3Completed · results123Sep 2, 2025
Bimatoprost (SR)Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionPhase 3Completed · results515Aug 8, 2025